Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroesophageal (GE) Junction Carcinomas and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
- The report reviews pipeline therapeutics for Gastroesophageal (GE) Junction Carcinomas by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastroesophageal (GE) Junction Carcinomas therapeutics and enlists all their major and minor projects
- The report assesses Gastroesophageal (GE) Junction Carcinomas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastroesophageal (GE) Junction Carcinomas
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abbisko Therapeutics Co LtdABL Bio Inc
Adaptimmune Therapeutics Plc
Adlai Nortye Biopharma Co Ltd
Affibody AB
Alligator Bioscience AB
Allorion Therapeutics Inc
Alphamab Oncology
Amgen Inc
Antengene Corp Ltd
Arbele Ltd
Arcus Biosciences Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Baiya Phytopharm Co Ltd
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Bio-Thera Solutions Ltd
Biotheus Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
CARsgen Therapeutics Ltd
Centrymed Pharmaceutical Inc
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
CTx Operations Inc
Cue Biopharma Inc
CytomX Therapeutics Inc
D3 Bio Inc
Delta-Fly Pharma Inc
Elevar Therapeutics Inc
Elevation Oncology Inc
Elucida Oncology Inc
Etern BioPharma Co Ltd
Eucure (Beijing) Biopharma Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fog Pharmaceuticals Inc
Genentech USA Inc
Genor BioPharma Co Ltd
GI Innovation Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
I-Mab
Idience Co Ltd
Iksuda Therapeutics Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneSensor Therapeutics Inc
ImmunityBio Inc
Immunome Inc
Incyte Corp
Innate Pharma SA
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
LaNova Medicines Ltd
Lepu Biopharma Co Ltd
LianBio
Lisata Therapeutics Inc
Luye Pharma Group Ltd
Lyvgen Biopharma Ltd
MacroGenics Inc
Merck KGaA
Mirati Therapeutics Inc
National Cancer Institute US
NextCure Inc
NextPoint Therapeutics Inc
Nouscom AG
Oncomatryx Biopharma SL
Ono Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd
Palleon Pharmaceuticals Inc
POINT Biopharma Global Inc
Precirix NV
Protheragen Inc
Purple Biotech Ltd
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qurient Co Ltd
RemeGen Co Ltd
Repare Therapeutics Inc
Replimune Ltd
Revolution Medicines Inc
Seagen Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai JMT-Bio Technology Co Ltd
Shanghai LiteDD Co Ltd
Shanghai Miracogen Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sosei Group Corp
Starpharma Holdings Ltd
Taiho Pharmaceutical Co Ltd
Tavotek Biotherapeutics
TCRx Therapeutics Co Ltd
Teclison Ltd
Tempest Therapeutics Inc
Toray Industries Inc
Transcenta Holding Ltd
Treadwell Therapeutics Inc
Triumvira Immunologics Inc
Turnstone Biologics Inc
United BioPharma Inc
Volastra Therapeutics Inc
Zai Lab Ltd
Zhejiang Doer Biologics Corp